Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
Ab176598-100μg
|
100μg |
10
|
$129.90
|
|
|
Ab176598-1mg
|
1mg |
4
|
$649.90
|
|
|
Ab176598-5mg
|
5mg |
1
|
$2,029.90
|
|
|
Ab176598-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$3,249.90
|
|
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG2SA; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Navicixizumab (anti-DLL4) - Primary antibody, specific to DLL4, >95%, high purity, Human IgG2SA |
|---|---|
| Synonyms | AOS6 antibody | Delta 4 antibody | delta 4 precursor antibody | Delta ligand 4 antibody | delta ligand 4 precursor antibody | Delta like 4 antibody | Delta like 4 homolog antibody | Delta like 4 protein antibody | Delta like canonical Notch ligand 4 antib |
| Specifications & Purity | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA |
| Host species | Human |
| Specificity | DLL4 |
| Conjugation | Unconjugated |
| Grade | Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Product Description |
Navicixizumab (anti-DLL4) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab (anti-DLL4) can combine with Paclitaxel (HY-B0015) for cancer research. Navicixizumab (anti-DLL4) can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer. |
| Isotype | Human IgG2SA |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 146.17 kDa |
| Purification Method | Protein A purified |
| Purity | >95% |
| Shape | Liquid |
| Concentration | See COA |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle. |
| CAS | 1638338-43-8 |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Navicixizumab (anti-DLL4) (Ab176598) - Flow Cytometry
Flow Cytometry analysis of HUVEC cells labelling DLL4 (red) with Navicixizumab (anti-DLL4) (Ab176598). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Navicixizumab (anti-DLL4) (Ab176598) - SEC
The purity of Navicixizumab (anti-DLL4) (Ab176598) is more than 95% verified by HPLC.
Navicixizumab (anti-DLL4) (Ab176598) - ELISA
Immobilized human-DLL4-his a at 2.0 μg/mL can bind Navicixizumab (anti-DLL4) (Ab176598) with the EC₅₀ of 36.01 ng/mL.
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
| Certificate of Analysis | Apr 11, 2024 | Ab176598 | |
| Certificate of Analysis | Apr 11, 2024 | Ab176598 | |
| Certificate of Analysis | Apr 11, 2024 | Ab176598 |
Starting at $89.90
Starting at $109.90